CardioNerds @AHA23: MINT: Myocardial Ischaemia & Transfusion

Published: 16 Nov 2023

  • Views:

    Views Icon 346
  • Likes:

    Heart Icon 1
Average (ratings)
No ratings
Your rating

AHA 2023 — Investigator, Dr Jeffrey Carson (Rutgers University, US) joined Dr Nazli Okumus, CardioNerds Ambassador to discuss findings from the MINT trial (NCT02981407). 

The aim of this randomised, parallel assignment trial (Rutgers) is to compare liberal and restrictive red blood cell transfusion strategies in patients who have had an acute myocardial infarction (AMI) and are anemic. Investigators enrolled 3,506 patients with AMI and a hemoglobin level less than 10 g/dL at 144 centers in the United States, Canada, France, Brazil, New Zealand and Australia. Patients will be randomized to either a liberal or restrictive transfusion strategy. The primary endpoint is a composite of all-cause death or recurrent MI within 30 days following randomization.

Findings presented at AHA showed that the MINT trial did not demonstrate a statistically significant recurrence in the rate of 30-day death or recurrent MI in patients with acute MI and anaemia assigned to a restrictive transfusion strategy as compared to a liberal strategy. While not statistically significant, point estimates for the primary outcome and secondary outcomes consistently favoured a liberal transfusion strategy. 

Recorded on-site at AHA 2023, Philadelphia.

Supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.


You must be to comment. If you are not registered, you can register here.